UNLABELLED: Cholesteryl ester storage disease (CESD) and Wolman disease are autosomal recessive later-onset and severe infantile disorders, respectively, which result from the deficient activity of lysosomal acid lipase (LAL). LAL is encoded by LIPA (10q23.31) and the most common mutation associated with CESD is an exon 8 splice junction mutation (c.894G>A; E8SJM), which expresses only ∼3%-5% of normally spliced LAL. However, the frequency of c.894G>A is unknown in most populations. To estimate the prevalence of CESD in different populations, the frequencies of the c.894G>A mutation were determined in 10,000 LIPA alleles from healthy African-American, Asian, Caucasian, Hispanic, and Ashkenazi Jewish individuals from the greater New York metropolitan area and 6,578 LIPA alleles from African-American, Caucasian, and Hispanic subjects enrolled in the Dallas Heart Study. The combined c.894G>A allele frequencies from the two cohorts ranged from 0.0005 (Asian) to 0.0017 (Caucasian and Hispanic), which translated to carrier frequencies of 1 in 1,000 to ∼1 in 300, respectively. No African-American heterozygotes were detected. Additionally, by surveying the available literature, c.894G>A was estimated to account for 60% (95% confidence interval [CI]: 51%-69%) of reported mutations among multiethnic CESD patients. Using this estimate, the predicted prevalence of CESD in the Caucasian and Hispanic populations is ∼0.8 per 100,000 (∼1 in 130,000; 95% CI: ∼1 in 90,000 to 1 in 170,000). CONCLUSION: These data indicate that CESD may be underdiagnosed in the general Caucasian and Hispanic populations, which is important since clinical trials of enzyme replacement therapy for LAL deficiency are currently being developed. Moreover, future studies on CESD prevalence in African and Asian populations may require full-gene LIPA sequencing to determine heterozygote frequencies, since c.894G>A is not common in these racial groups.
UNLABELLED: Cholesteryl ester storage disease (CESD) and Wolman disease are autosomal recessive later-onset and severe infantile disorders, respectively, which result from the deficient activity of lysosomal acid lipase (LAL). LAL is encoded by LIPA (10q23.31) and the most common mutation associated with CESD is an exon 8 splice junction mutation (c.894G>A; E8SJM), which expresses only ∼3%-5% of normally spliced LAL. However, the frequency of c.894G>A is unknown in most populations. To estimate the prevalence of CESD in different populations, the frequencies of the c.894G>A mutation were determined in 10,000 LIPA alleles from healthy African-American, Asian, Caucasian, Hispanic, and Ashkenazi Jewish individuals from the greater New York metropolitan area and 6,578 LIPA alleles from African-American, Caucasian, and Hispanic subjects enrolled in the Dallas Heart Study. The combined c.894G>A allele frequencies from the two cohorts ranged from 0.0005 (Asian) to 0.0017 (Caucasian and Hispanic), which translated to carrier frequencies of 1 in 1,000 to ∼1 in 300, respectively. No African-American heterozygotes were detected. Additionally, by surveying the available literature, c.894G>A was estimated to account for 60% (95% confidence interval [CI]: 51%-69%) of reported mutations among multiethnic CESDpatients. Using this estimate, the predicted prevalence of CESD in the Caucasian and Hispanic populations is ∼0.8 per 100,000 (∼1 in 130,000; 95% CI: ∼1 in 90,000 to 1 in 170,000). CONCLUSION: These data indicate that CESD may be underdiagnosed in the general Caucasian and Hispanic populations, which is important since clinical trials of enzyme replacement therapy for LAL deficiency are currently being developed. Moreover, future studies on CESD prevalence in African and Asian populations may require full-gene LIPA sequencing to determine heterozygote frequencies, since c.894G>A is not common in these racial groups.
Authors: Uta Drebber; Matthias Andersen; Hans U Kasper; Peter Lohse; Manfred Stolte; Hans P Dienes Journal: World J Gastroenterol Date: 2005-04-21 Impact factor: 5.742
Authors: S Ries; C Büchler; G Schindler; C Aslanidis; D Ameis; C Gasche; N Jung; A Schambach; P Fehringer; M T Vanier; D C Belli; H Greten; G Schmitz Journal: Hum Mutat Date: 1998 Impact factor: 4.878
Authors: Amal Aqul; Adam M Lopez; Kenneth S Posey; Anna M Taylor; Joyce J Repa; Dennis K Burns; Stephen D Turley Journal: Am J Physiol Gastrointest Liver Physiol Date: 2014-08-21 Impact factor: 4.052
Authors: Yuritzi Santillán-Hernández; Enory Almanza-Miranda; Winnie W Xin; Kendrick Goss; Aurea Vera-Loaiza; María T Gorráez-de la Mora; Raul E Piña-Aguilar Journal: World J Gastroenterol Date: 2015-01-21 Impact factor: 5.742
Authors: Sylvia T Nurnberg; Hanrui Zhang; Nicholas J Hand; Robert C Bauer; Danish Saleheen; Muredach P Reilly; Daniel J Rader Journal: Circ Res Date: 2016-02-19 Impact factor: 17.367
Authors: Nathan O Stitziel; Sigrid W Fouchier; Barbara Sjouke; Gina M Peloso; Alessa M Moscoso; Paul L Auer; Anuj Goel; Bruna Gigante; Timothy A Barnes; Olle Melander; Marju Orho-Melander; Stefano Duga; Suthesh Sivapalaratnam; Majid Nikpay; Nicola Martinelli; Domenico Girelli; Rebecca D Jackson; Charles Kooperberg; Leslie A Lange; Diego Ardissino; Ruth McPherson; Martin Farrall; Hugh Watkins; Muredach P Reilly; Daniel J Rader; Ulf de Faire; Heribert Schunkert; Jeanette Erdmann; Nilesh J Samani; Lawrence Charnas; David Altshuler; Stacey Gabriel; John J P Kastelein; Joep C Defesche; Aart J Nederveen; Sekar Kathiresan; G Kees Hovingh Journal: Arterioscler Thromb Vasc Biol Date: 2013-09-26 Impact factor: 8.311
Authors: Ariel Brautbar; Emili Leary; Kristen Rasmussen; Don P Wilson; Robert D Steiner; Salim Virani Journal: Curr Atheroscler Rep Date: 2015-04 Impact factor: 5.113
Authors: Vassili Valayannopoulos; Vera Malinova; Tomas Honzík; Manisha Balwani; Catherine Breen; Patrick B Deegan; Gregory M Enns; Simon A Jones; John P Kane; Eveline O Stock; Radhika Tripuraneni; Stephen Eckert; Eugene Schneider; Gavin Hamilton; Michael S Middleton; Claude Sirlin; Bruce Kessler; Christopher Bourdon; Simeon A Boyadjiev; Reena Sharma; Chris Twelves; Chester B Whitley; Anthony G Quinn Journal: J Hepatol Date: 2014-06-30 Impact factor: 25.083